News for Acurx Pharmaceuticals, Inc. (ACXP)

PR NewswireSTATEN ISLAND, N.Y., July 24, 2025 STATEN ISLAND, N.Y., July 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the

Acurx Pharmaceuticals (ACXP) will conduct its Q2 2025 financial results conference call on August 12, 2025, at 8:00 AM ET. The call will be hosted by CE

Acurx Pharmaceuticals (ACXP) has initiated the process to offer 9.16 million shares of its common stock. This move is aimed at providing existing shareholders a

Key Takeaways: Acurx Pharmaceuticals (ACXP) has filed a shelf registration to raise up to $50 million. Analysts project significant upside potential with

Acurx Pharmaceuticals (ACXP) has announced a significant financial strategy by filing with the SEC for a $50 million mixed securities shelf offering. This move

Acurx Pharmaceuticals (ACXP) files $50M shelf registration for securities offering. Explore potential investments in common stock, debt securities, and more.

PR NewswireSTATEN ISLAND, N.Y., June 17, 2025 In the news release, Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proce

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

Shares of Beyond Air, Inc. XAIR fell sharply in today's pre-market trading after the company posted mixed fourth-quarter results. Beyond Air reported quarterly...

Acurx Pharmaceuticals (ACXP) secured $2.67 million through warrant exercise at a reduced price. New warrants with a $0.425 exercise price provid

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Tuesday. The Dow traded down 0.70% to 42,217.89 w...

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded do...

Acurx Pharmaceuticals (ACXP) is progressing its leading antibiotic candidate, ibezapolstat, into international Phase 3 clinical trials aimed at treating C. diff

Key Highlights: Acurx Pharmaceuticals (ACXP) announced 94% clinical cure rate for ibezapolstat, with zero recurrence in Phase 2b trial

Acurx Pharmaceuticals (ACXP), focused on developing pioneering small molecule antibiotics, is progressing its lead candidate, ibezapolstat, towards pivotal Phas

Ibezapolstat advances to pivotal Phase 3 trials for C. difficile Infection. Received FDA QIDP, Fast-Track, and EMA SME designations. Rese

ACXP has announced that the company itself will not be offering any securities for sale under the current prospectus. Consequently, ACXP will not benefit from a

H.C. Wainwright has begun coverage of Acurx Pharmaceuticals (ACXP) with a recommendation to buy, setting a price target of $8. Acurx is a pharmaceutical company

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsRobert Shawah - Co-Founder and...